Recent Analyst Stock Rating News
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.Get Started for Free
Evan Seigerman is an analyst at BMO Capital. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 04/11/2025
| Buy Now | Get Alert | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 02/13/2025 | BIIB | Buy Now | Biogen | $114.51 | 21.39% | Evan Seigerman65% | $156 → $139 | Maintains | Market Perform | Get Alert |
| 02/12/2025 | GILD | Buy Now | Gilead Sciences | $101.30 | 13.52% | Evan Seigerman65% | $110 → $115 | Maintains | Outperform | Get Alert |
| 12/20/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $475.49 | 9.36% | Evan Seigerman65% | $566 → $520 | Maintains | Outperform | Get Alert |
| 12/20/2024 | BIIB | Buy Now | Biogen | $114.51 | 43.22% | Evan Seigerman65% | $230 → $164 | Downgrade | Outperform → Market Perform | Get Alert |
| 11/12/2024 | BMY | Buy Now | Bristol-Myers Squibb | $50.44 | 20.94% | Evan Seigerman65% | $57 → $61 | Maintains | Market Perform | Get Alert |
| 11/07/2024 | GILD | Buy Now | Gilead Sciences | $101.30 | 0.69% | Evan Seigerman65% | $94 → $102 | Maintains | Outperform | Get Alert |
| 11/01/2024 | BMY | Buy Now | Bristol-Myers Squibb | $50.44 | 13.01% | Evan Seigerman65% | $53 → $57 | Maintains | Market Perform | Get Alert |
| 10/30/2024 | INCY | Buy Now | Incyte | $55.17 | -5.75% | Evan Seigerman65% | $48 → $52 | Reiterates | Underperform → Underperform | Get Alert |
| 10/17/2024 | NBIX | Buy Now | Neurocrine Biosciences | $90.70 | 25.69% | Evan Seigerman65% | $128 → $114 | Maintains | Market Perform | Get Alert |
| 10/17/2024 | GILD | Buy Now | Gilead Sciences | $101.30 | -7.21% | Evan Seigerman65% | $85 → $94 | Maintains | Outperform | Get Alert |
| 10/17/2024 | BIIB | Buy Now | Biogen | $114.51 | 100.86% | Evan Seigerman65% | $260 → $230 | Maintains | Outperform | Get Alert |
| 09/27/2024 | BMY | Buy Now | Bristol-Myers Squibb | $50.44 | 5.08% | Evan Seigerman65% | $48 → $53 | Maintains | Market Perform | Get Alert |
| 09/23/2024 | BMY | Buy Now | Bristol-Myers Squibb | $50.44 | -4.84% | Evan Seigerman65% | $48 → $48 | Maintains | Market Perform | Get Alert |
| 08/29/2024 | NBIX | Buy Now | Neurocrine Biosciences | $90.70 | 41.12% | Evan Seigerman65% | $142 → $128 | Maintains | Market Perform | Get Alert |
| 08/09/2024 | LLY | Buy Now | Eli Lilly | $727.12 | 51.42% | Evan Seigerman65% | $1001 → $1101 | Maintains | Outperform | Get Alert |
| 08/09/2024 | GILD | Buy Now | Gilead Sciences | $101.30 | -16.09% | Evan Seigerman65% | $80 → $85 | Maintains | Outperform | Get Alert |
| 07/03/2024 | LLY | Buy Now | Eli Lilly and Co | $727.12 | 37.67% | Evan Seigerman65% | $1001 → $1001 | Maintains | Outperform | Get Alert |
| 07/02/2024 | INCY | Buy Now | Incyte | $55.17 | -13% | Evan Seigerman65% | $52 → $48 | Downgrade | Market Perform → Underperform | Get Alert |
| 06/17/2024 | IRON | Buy Now | Disc Medicine | $39.40 | 77.66% | Evan Seigerman65% | $50 → $70 | Reiterates | Outperform → Outperform | Get Alert |
| 05/31/2024 | VRTX | Buy Now | Vertex Pharmaceuticals | $475.49 | 5.15% | Evan Seigerman65% | $480 → $500 | Maintains | Outperform | Get Alert |
| 05/02/2024 | NBIX | Buy Now | Neurocrine Biosciences | $90.70 | 52.15% | Evan Seigerman65% | $129 → $138 | Maintains | Market Perform | Get Alert |
| 05/01/2024 | LLY | Buy Now | Eli Lilly and Co | $727.12 | 37.67% | Evan Seigerman65% | $900 → $1001 | Maintains | Outperform | Get Alert |
| 05/01/2024 | INCY | Buy Now | Incyte | $55.17 | -5.75% | Evan Seigerman65% | $56 → $52 | Maintains | Market Perform | Get Alert |
| 04/26/2024 | BMY | Buy Now | Bristol-Myers Squibb | $50.44 | -4.84% | Evan Seigerman65% | $55 → $48 | Maintains | Market Perform | Get Alert |
| 04/02/2024 | IRON | Buy Now | Disc Medicine | $39.40 | 26.9% | Evan Seigerman65% | $80 → $50 | Maintains | Outperform | Get Alert |
| 02/29/2024 | IRON | Buy Now | Disc Medicine | $39.40 | 103.05% | Evan Seigerman65% | $70 → $80 | Maintains | Outperform | Get Alert |
| 02/14/2024 | BIIB | Buy Now | Biogen | $114.51 | 148.89% | Evan Seigerman65% | $295 → $285 | Maintains | Outperform | Get Alert |
| 02/14/2024 | INCY | Buy Now | Incyte | $55.17 | 16.01% | Evan Seigerman65% | $58 → $64 | Maintains | Market Perform | Get Alert |
| 02/07/2024 | LLY | Buy Now | Eli Lilly | $727.12 | 18.96% | Evan Seigerman65% | $710 → $865 | Maintains | Outperform | Get Alert |
| 11/10/2023 | NBIX | Buy Now | Neurocrine Biosciences | $90.70 | 10.25% | Evan Seigerman65% | $111 → $100 | Maintains | Market Perform | Get Alert |
| 11/09/2023 | BIIB | Buy Now | Biogen | $114.51 | 157.62% | Evan Seigerman65% | $314 → $295 | Maintains | Outperform | Get Alert |
| 11/07/2023 | VRTX | Buy Now | Vertex Pharmaceuticals | $475.49 | -12.72% | Evan Seigerman65% | $389 → $415 | Maintains | Outperform | Get Alert |
| 10/27/2023 | BMY | Buy Now | Bristol-Myers Squibb | $50.44 | 18.95% | Evan Seigerman65% | → $60 | Downgrade | Outperform → Market Perform | Get Alert |
| 09/13/2023 | NBIX | Buy Now | Neurocrine Biosciences | $90.70 | 22.38% | Evan Seigerman65% | $100 → $111 | Maintains | Market Perform | Get Alert |
| 08/09/2023 | LLY | Buy Now | Eli Lilly | $727.12 | -12.94% | Evan Seigerman65% | $565 → $633 | Maintains | Outperform | Get Alert |
| 08/08/2023 | BIIB | Buy Now | Biogen | $114.51 | 193.42% | Evan Seigerman65% | $347 → $336 | Maintains | Outperform | Get Alert |
| 08/02/2023 | INCY | Buy Now | Incyte | $55.17 | 23.26% | Evan Seigerman65% | $70 → $68 | Maintains | Market Perform | Get Alert |
| 08/02/2023 | VRTX | Buy Now | Vertex Pharmaceuticals | $475.49 | -18.19% | Evan Seigerman65% | $385 → $389 | Maintains | Outperform | Get Alert |
| 08/02/2023 | NBIX | Buy Now | Neurocrine Biosciences | $90.70 | 10.25% | Evan Seigerman65% | $96 → $100 | Maintains | Market Perform | Get Alert |
| 07/28/2023 | BMY | Buy Now | Bristol-Myers Squibb | $50.44 | 56.62% | Evan Seigerman65% | $87 → $79 | Maintains | Outperform | Get Alert |
| 07/26/2023 | BIIB | Buy Now | Biogen | $114.51 | 203.03% | Evan Seigerman65% | $357 → $347 | Maintains | Outperform | Get Alert |
| 07/06/2023 | NBIX | Buy Now | Neurocrine Biosciences | $90.70 | 5.84% | Evan Seigerman65% | $91 → $96 | Upgrade | Underperform → Market Perform | Get Alert |
| 06/12/2023 | IRON | Buy Now | Disc Medicine | $39.40 | 77.66% | Evan Seigerman65% | $40 → $70 | Maintains | Outperform | Get Alert |
| 05/16/2023 | GILD | Buy Now | Gilead Sciences | $101.30 | -1.28% | Evan Seigerman65% | $90 → $100 | Upgrade | Market Perform → Outperform | Get Alert |
| 05/04/2023 | LLY | Buy Now | Eli Lilly | $727.12 | -30.55% | Evan Seigerman65% | $430 → $505 | Maintains | Outperform | Get Alert |
| 05/03/2023 | INCY | Buy Now | Incyte | $55.17 | 26.88% | Evan Seigerman65% | $75 → $70 | Maintains | Market Perform | Get Alert |
| 05/02/2023 | VRTX | Buy Now | Vertex Pharmaceuticals | $475.49 | -19.03% | Evan Seigerman65% | → $385 | Maintains | Outperform | Get Alert |
| 03/23/2023 | IRON | Buy Now | Disc Medicine | $39.40 | 1.52% | Evan Seigerman65% | → $40 | Initiates | → Outperform | Get Alert |
| 02/28/2023 | GPCR | Buy Now | Structure Therapeutics | $15.05 | 165.78% | Evan Seigerman65% | → $40 | Initiates | → Outperform | Get Alert |
| 02/08/2023 | VRTX | Buy Now | Vertex Pharmaceuticals | $475.49 | -25.34% | Evan Seigerman65% | → $355 | Maintains | Outperform | Get Alert |
| 12/08/2022 | MRTX | Buy Now | Mirati Therapeutics | — | — | Evan Seigerman65% | $110 → $59 | Downgrade | Outperform → Market Perform | Get Alert |
| 10/14/2022 | REPL | Buy Now | Replimune Group | $6.74 | 493.47% | Evan Seigerman65% | $30 → $40 | Maintains | Outperform | Get Alert |
| 09/28/2022 | BIIB | Buy Now | Biogen | $114.51 | 214.38% | Evan Seigerman65% | $217 → $360 | Upgrade | Market Perform → Outperform | Get Alert |
| 09/12/2022 | BMY | Buy Now | Bristol-Myers Squibb | $50.44 | 86.36% | Evan Seigerman65% | $92 → $94 | Maintains | Outperform | Get Alert |
| 08/04/2022 | REGN | Buy Now | Regeneron Pharmaceuticals | $546.03 | 44.31% | Evan Seigerman65% | $757 → $788 | Maintains | Outperform | Get Alert |
| 08/02/2022 | NUVB | Buy Now | Nuvation Bio | $1.83 | 36.61% | Evan Seigerman65% | $8 → $2.5 | Downgrade | Outperform → Market Perform | Get Alert |
| 05/02/2022 | BMY | Buy Now | Bristol-Myers Squibb | $50.44 | 82.39% | Evan Seigerman65% | $87 → $92 | Maintains | Outperform | Get Alert |
| 04/29/2022 | GILD | Buy Now | Gilead Sciences | $101.30 | -37.81% | Evan Seigerman65% | $65 → $63 | Maintains | Market Perform | Get Alert |
| 04/29/2022 | LLY | Buy Now | Eli Lilly | $727.12 | -50.76% | Evan Seigerman65% | $330 → $358 | Maintains | Outperform | Get Alert |
| 04/28/2022 | AMGN | Buy Now | Amgen | $282.50 | -13.98% | Evan Seigerman65% | $263 → $243 | Maintains | Market Perform | Get Alert |
| 03/31/2022 | CADL | Buy Now | Candel Therapeutics | $5.00 | 140% | Evan Seigerman65% | $18 → $12 | Maintains | Outperform | Get Alert |
| 03/30/2022 | BMY | Buy Now | Bristol-Myers Squibb | $50.44 | 60.59% | Evan Seigerman65% | $74 → $81 | Maintains | Outperform | Get Alert |
| 03/22/2022 | NUVB | Buy Now | Nuvation Bio | $1.83 | 555.74% | Evan Seigerman65% | $17 → $12 | Maintains | Outperform | Get Alert |
| 02/28/2022 | GILD | Buy Now | Gilead Sciences | $101.30 | -35.83% | Evan Seigerman65% | $75 → $65 | Downgrade | Outperform → Market Perform | Get Alert |
| 02/04/2022 | BIIB | Buy Now | Biogen | $114.51 | 107.84% | Evan Seigerman65% | $260 → $238 | Downgrade | Outperform → Market Perform | Get Alert |
| 01/20/2022 | VRTX | Buy Now | Vertex Pharmaceuticals | $475.49 | -42.38% | Evan Seigerman65% | $202 → $274 | Upgrade | Market Perform → Outperform | Get Alert |
| 11/19/2021 | CADL | Buy Now | Candel Therapeutics | $5.00 | 260% | Evan Seigerman65% | → $18 | Initiates | → Outperform | Get Alert |
| 11/19/2021 | MRTX | Buy Now | Mirati Therapeutics | — | — | Evan Seigerman65% | → $187 | Initiates | → Outperform | Get Alert |
| 11/19/2021 | PFE | Buy Now | Pfizer | $21.74 | 175.99% | Evan Seigerman65% | → $60 | Initiates | → Outperform | Get Alert |
| 11/19/2021 | BMY | Buy Now | Bristol-Myers Squibb | $50.44 | 42.74% | Evan Seigerman65% | → $72 | Initiates | → Outperform | Get Alert |
| 11/19/2021 | LLY | Buy Now | Eli Lilly | $727.12 | -57.23% | Evan Seigerman65% | → $311 | Initiates | → Outperform | Get Alert |
| 11/19/2021 | INCY | Buy Now | Incyte | $55.17 | 35.94% | Evan Seigerman65% | → $75 | Initiates | → Market Perform | Get Alert |
| 11/19/2021 | BIIB | Buy Now | Biogen | $114.51 | 175.09% | Evan Seigerman65% | → $315 | Initiates | → Outperform | Get Alert |
| 11/19/2021 | AMGN | Buy Now | Amgen | $282.50 | -19.29% | Evan Seigerman65% | → $228 | Initiates | → Market Perform | Get Alert |
| 11/19/2021 | NBIX | Buy Now | Neurocrine Biosciences | $90.70 | -16.21% | Evan Seigerman65% | → $76 | Initiates | → Underperform | Get Alert |
| 11/19/2021 | VRTX | Buy Now | Vertex Pharmaceuticals | $475.49 | -57.52% | Evan Seigerman65% | → $202 | Initiates | → Market Perform | Get Alert |
| 08/13/2021 | IKNA | Buy Now | Ikena Oncology | $1.02 | 2547.06% | Evan Seigerman65% | $30 → $27 | Maintains | Outperform | Get Alert |
| 04/20/2021 | IKNA | Buy Now | Ikena Oncology | $1.02 | 2841.18% | Evan Seigerman65% | → $30 | Initiates | → Outperform | Get Alert |
| 03/02/2021 | STSA | Buy Now | Satsuma Pharma | — | — | Evan Seigerman65% | → $6.5 | Upgrade | Underperform → Neutral | Get Alert |
| 02/23/2021 | REGN | Buy Now | Regeneron Pharmaceuticals | $546.03 | 39.19% | Evan Seigerman65% | $753 → $760 | Maintains | Outperform | Get Alert |
| 02/08/2021 | REGN | Buy Now | Regeneron Pharmaceuticals | $546.03 | 37.9% | Evan Seigerman65% | $758 → $753 | Maintains | Outperform | Get Alert |
| 02/05/2021 | GILD | Buy Now | Gilead Sciences | $101.30 | -34.85% | Evan Seigerman65% | $65 → $66 | Maintains | Neutral | Get Alert |
| 02/04/2021 | BIIB | Buy Now | Biogen | $114.51 | 195.17% | Evan Seigerman65% | $350 → $338 | Maintains | Outperform | Get Alert |
| 02/03/2021 | AMGN | Buy Now | Amgen | $282.50 | -6.19% | Evan Seigerman65% | $280 → $265 | Maintains | Outperform | Get Alert |
| 02/02/2021 | VRTX | Buy Now | Vertex Pharmaceuticals | $475.49 | -41.11% | Evan Seigerman65% | $285 → $280 | Maintains | Outperform | Get Alert |
| 12/16/2020 | MRTX | Buy Now | Mirati Therapeutics | — | — | Evan Seigerman65% | $225 → $285 | Maintains | Outperform | Get Alert |
| 12/16/2020 | REGN | Buy Now | Regeneron Pharmaceuticals | $546.03 | 34.79% | Evan Seigerman65% | $737 → $736 | Maintains | Outperform | Get Alert |
| 12/16/2020 | GILD | Buy Now | Gilead Sciences | $101.30 | -35.83% | Evan Seigerman65% | $70 → $65 | Maintains | Neutral | Get Alert |
| 12/16/2020 | GRTX | Buy Now | Galera Therapeutics | $0.03 | 57815.06% | Evan Seigerman65% | $9 → $15 | Upgrade | Neutral → Outperform | Get Alert |
| 11/11/2020 | GRTX | Buy Now | Galera Therapeutics | $0.03 | 34649.03% | Evan Seigerman65% | $8 → $9 | Maintains | Neutral | Get Alert |
| 11/10/2020 | NBIX | Buy Now | Neurocrine Biosciences | $90.70 | -0.77% | Evan Seigerman65% | $105 → $90 | Maintains | Neutral | Get Alert |
| 11/06/2020 | REGN | Buy Now | Regeneron Pharmaceuticals | $546.03 | 34.97% | Evan Seigerman65% | $745 → $737 | Maintains | Outperform | Get Alert |
| 10/30/2020 | VRTX | Buy Now | Vertex Pharmaceuticals | $475.49 | -40.06% | Evan Seigerman65% | $292 → $285 | Maintains | Outperform | Get Alert |
| 10/27/2020 | MRTX | Buy Now | Mirati Therapeutics | — | — | Evan Seigerman65% | $190 → $225 | Maintains | Outperform | Get Alert |
| 10/27/2020 | AMGN | Buy Now | Amgen | $282.50 | 0.53% | Evan Seigerman65% | $286 → $284 | Maintains | Outperform | Get Alert |
| 10/22/2020 | BIIB | Buy Now | Biogen | $114.51 | 205.65% | Evan Seigerman65% | $359 → $350 | Maintains | Outperform | Get Alert |
| 10/08/2020 | MRTX | Buy Now | Mirati Therapeutics | — | — | Evan Seigerman65% | $140 → $190 | Reiterates | → Outperform | Get Alert |
| 09/11/2020 | STSA | Buy Now | Satsuma Pharma | — | — | Evan Seigerman65% | $33 → $4 | Downgrade | Outperform → Underperform | Get Alert |
| 09/01/2020 | AIMT | Buy Now | Aimmune Therapeutics | — | — | Evan Seigerman65% | $14 → $34.5 | Maintains | Neutral | Get Alert |
| 08/14/2020 | STSA | Buy Now | Satsuma Pharma | — | — | Evan Seigerman65% | $32 → $33 | Maintains | Outperform | Get Alert |
| 08/13/2020 | ACRX | Buy Now | AcelRx Pharmaceuticals | — | — | Evan Seigerman65% | $13.8 → $16.8 | Maintains | Underperform | Get Alert |
| 08/07/2020 | MRTX | Buy Now | Mirati Therapeutics | — | — | Evan Seigerman65% | $135 → $140 | Maintains | Outperform | Get Alert |
| 08/07/2020 | REGN | Buy Now | Regeneron Pharmaceuticals | $546.03 | 32.78% | Evan Seigerman65% | $716 → $725 | Maintains | Outperform | Get Alert |
| 08/06/2020 | INCY | Buy Now | Incyte | $55.17 | 75.82% | Evan Seigerman65% | $100 → $97 | Maintains | Neutral | Get Alert |
| 08/04/2020 | NBIX | Buy Now | Neurocrine Biosciences | $90.70 | 38.92% | Evan Seigerman65% | $135 → $126 | Maintains | Neutral | Get Alert |
| 07/31/2020 | GILD | Buy Now | Gilead Sciences | $101.30 | -27.94% | Evan Seigerman65% | $75 → $73 | Maintains | Neutral | Get Alert |
| 07/29/2020 | GRTX | Buy Now | Galera Therapeutics | $0.03 | 30788.03% | Evan Seigerman65% | $14 → $8 | Maintains | Neutral | Get Alert |
| 07/29/2020 | MRTX | Buy Now | Mirati Therapeutics | — | — | Evan Seigerman65% | $115 → $135 | Maintains | Outperform | Get Alert |
| 07/29/2020 | AIMT | Buy Now | Aimmune Therapeutics | — | — | Evan Seigerman65% | $19 → $15 | Maintains | Neutral | Get Alert |
| 07/20/2020 | VRTX | Buy Now | Vertex Pharmaceuticals | $475.49 | -31.02% | Evan Seigerman65% | $298 → $328 | Maintains | Outperform | Get Alert |
| 07/20/2020 | REGN | Buy Now | Regeneron Pharmaceuticals | $546.03 | 31.13% | Evan Seigerman65% | $700 → $716 | Maintains | Outperform | Get Alert |
| 07/20/2020 | NBIX | Buy Now | Neurocrine Biosciences | $90.70 | 48.84% | Evan Seigerman65% | $101 → $135 | Maintains | Neutral | Get Alert |
| 07/20/2020 | INCY | Buy Now | Incyte | $55.17 | 81.26% | Evan Seigerman65% | $88 → $100 | Maintains | Neutral | Get Alert |
| 07/20/2020 | AMGN | Buy Now | Amgen | $282.50 | 2.65% | Evan Seigerman65% | $252 → $290 | Maintains | Outperform | Get Alert |
| 07/20/2020 | GILD | Buy Now | Gilead Sciences | $101.30 | -25.96% | Evan Seigerman65% | $64 → $75 | Upgrade | Underperform → Neutral | Get Alert |
| 07/20/2020 | ACRX | Buy Now | AcelRx Pharmaceuticals | — | — | Evan Seigerman65% | $20 → $13.8 | Downgrade | Neutral → Underperform | Get Alert |
| 06/24/2020 | REGN | Buy Now | Regeneron Pharmaceuticals | $546.03 | 28.2% | Evan Seigerman65% | $605 → $700 | Maintains | Outperform | Get Alert |
| 05/13/2020 | AIMT | Buy Now | Aimmune Therapeutics | — | — | Evan Seigerman65% | $29 → $19 | Maintains | Neutral | Get Alert |
| 05/12/2020 | MGNX | Buy Now | Macrogenics | $1.29 | 2225.58% | Evan Seigerman65% | $13 → $30 | Maintains | Outperform | Get Alert |
| 05/06/2020 | MGNX | Buy Now | Macrogenics | $1.29 | 907.75% | Evan Seigerman65% | $17 → $13 | Maintains | Outperform | Get Alert |
| 05/06/2020 | REGN | Buy Now | Regeneron Pharmaceuticals | $546.03 | 10.8% | Evan Seigerman65% | $596 → $605 | Maintains | Outperform | Get Alert |
| 04/23/2020 | BIIB | Buy Now | Biogen | $114.51 | 170.72% | Evan Seigerman65% | $344 → $310 | Maintains | Neutral | Get Alert |
| 04/21/2020 | VRTX | Buy Now | Vertex Pharmaceuticals | $475.49 | -37.33% | Evan Seigerman65% | $258 → $298 | Maintains | Outperform | Get Alert |
| 03/11/2020 | INCY | Buy Now | Incyte | $55.17 | 46.82% | Evan Seigerman65% | $86 → $81 | Maintains | Neutral | Get Alert |
| 02/26/2020 | REGN | Buy Now | Regeneron Pharmaceuticals | $546.03 | -6.6% | Evan Seigerman65% | $420 → $510 | Maintains | Outperform | Get Alert |
| 02/06/2020 | BIIB | Buy Now | Biogen | $114.51 | 188.18% | Evan Seigerman65% | $300 → $330 | Maintains | Neutral | Get Alert |
| 02/05/2020 | GILD | Buy Now | Gilead Sciences | $101.30 | -40.77% | Evan Seigerman65% | $59 → $60 | Maintains | Underperform | Get Alert |
| 01/31/2020 | VRTX | Buy Now | Vertex Pharmaceuticals | $475.49 | -45.74% | Evan Seigerman65% | $253 → $258 | Maintains | Outperform | Get Alert |
| 01/03/2020 | INCY | Buy Now | Incyte | $55.17 | 55.88% | Evan Seigerman65% | $90 → $86 | Maintains | Neutral | Get Alert |
| 12/13/2019 | NBIX | Buy Now | Neurocrine Biosciences | $90.70 | 21.28% | Evan Seigerman65% | → $110 | Downgrade | Outperform → Neutral | Get Alert |
| 12/13/2019 | GILD | Buy Now | Gilead Sciences | $101.30 | -37.81% | Evan Seigerman65% | $67 → $63 | Downgrade | Neutral → Underperform | Get Alert |
| 12/13/2019 | AIMT | Buy Now | Aimmune Therapeutics | — | — | Evan Seigerman65% | — | Downgrade | Outperform → Neutral | Get Alert |
| 12/13/2019 | BIIB | Buy Now | Biogen | $114.51 | 161.99% | Evan Seigerman65% | $260 → $300 | Upgrade | Underperform → Neutral | Get Alert |
| 12/13/2019 | REGN | Buy Now | Regeneron Pharmaceuticals | $546.03 | — | Evan Seigerman65% | — | Upgrade | Neutral → Outperform | Get Alert |
| 12/02/2019 | GRTX | Buy Now | Galera Therapeutics | $0.03 | 53954.05% | Evan Seigerman65% | → $14 | Initiates | → Neutral | Get Alert |
| 11/11/2019 | ACRX | Buy Now | AcelRx Pharmaceuticals | — | — | Evan Seigerman65% | $140 → $40 | Downgrade | Outperform → Neutral | Get Alert |
| 11/06/2019 | REGN | Buy Now | Regeneron Pharmaceuticals | $546.03 | -37.73% | Evan Seigerman65% | $310 → $340 | Maintains | Neutral | Get Alert |
| 10/23/2019 | BIIB | Buy Now | Biogen | $114.51 | 127.05% | Evan Seigerman65% | $203 → $260 | Maintains | Underperform | Get Alert |
| 10/08/2019 | STSA | Buy Now | Satsuma Pharma | — | — | Evan Seigerman65% | → $16 | Initiates | → Outperform | Get Alert |
| 08/16/2019 | AMGN | Buy Now | Amgen | $282.50 | -20.35% | Evan Seigerman65% | $202 → $225 | Reiterates | → Outperform | Get Alert |
| 08/05/2019 | ACRX | Buy Now | AcelRx Pharmaceuticals | — | — | Evan Seigerman65% | → $140 | Assumes | → Outperform | Get Alert |
| 08/01/2019 | VRTX | Buy Now | Vertex Pharmaceuticals | $475.49 | -55.2% | Evan Seigerman65% | $209 → $213 | Maintains | Outperform | Get Alert |
| 07/31/2019 | GILD | Buy Now | Gilead Sciences | $101.30 | -33.86% | Evan Seigerman65% | $70 → $67 | Maintains | Neutral | Get Alert |
| 07/30/2019 | NBIX | Buy Now | Neurocrine Biosciences | $90.70 | 21.28% | Evan Seigerman65% | $95 → $110 | Maintains | Outperform | Get Alert |
| 07/10/2019 | ACRX | Buy Now | AcelRx Pharmaceuticals | — | — | Evan Seigerman65% | — | Assumes | → Outperform | Get Alert |
| 05/21/2019 | INCY | Buy Now | Incyte | $55.17 | 35.94% | Evan Seigerman65% | → $75 | Initiates | → Neutral | Get Alert |
| 05/21/2019 | GILD | Buy Now | Gilead Sciences | $101.30 | -30.9% | Evan Seigerman65% | → $70 | Initiates | → Neutral | Get Alert |
| 05/21/2019 | NBIX | Buy Now | Neurocrine Biosciences | $90.70 | 4.74% | Evan Seigerman65% | → $95 | Initiates | → Outperform | Get Alert |
| 05/21/2019 | BIIB | Buy Now | Biogen | $114.51 | 72.91% | Evan Seigerman65% | → $198 | Initiates | → Underperform | Get Alert |
| 05/21/2019 | REGN | Buy Now | Regeneron Pharmaceuticals | $546.03 | -38.46% | Evan Seigerman65% | → $336 | Initiates | → Neutral | Get Alert |
| 04/17/2019 | MGNX | Buy Now | Macrogenics | $1.29 | 2148.06% | Evan Seigerman65% | → $29 | Initiates | → Outperform | Get Alert |
| 03/25/2019 | MRTX | Buy Now | Mirati Therapeutics | — | — | Evan Seigerman65% | → $85 | Initiates | → Outperform | Get Alert |
| 02/15/2019 | ACRX | Buy Now | AcelRx Pharmaceuticals | — | — | Evan Seigerman65% | → $140 | Initiates | → Outperform | Get Alert |
| 01/20/2016 | BIIB | Buy Now | Biogen | $114.51 | 181.2% | Evan Seigerman65% | → $322 | Initiates | → Neutral | Get Alert |
| 01/20/2016 | REGN | Buy Now | Regeneron Pharmaceuticals | $546.03 | 1.09% | Evan Seigerman65% | → $552 | Initiates | → Neutral | Get Alert |
| 05/06/2015 | REGN | Buy Now | Regeneron Pharmaceuticals | $546.03 | -26.74% | Evan Seigerman65% | → $400 | Assumes | → Outperform | Get Alert |
| 11/19/2014 | BIIB | Buy Now | Biogen | $114.51 | 249.31% | Evan Seigerman65% | $425 → $400 | Maintains | Outperform | Get Alert |
| 09/02/2014 | REGN | Buy Now | Regeneron Pharmaceuticals | $546.03 | -26.74% | Evan Seigerman65% | $340 → $400 | Maintains | Outperform | Get Alert |
| 07/24/2014 | BIIB | Buy Now | Biogen | $114.51 | 271.15% | Evan Seigerman65% | $400 → $425 | Maintains | Outperform | Get Alert |
| 02/14/2014 | BIIB | Buy Now | Biogen | $114.51 | 249.31% | Evan Seigerman65% | $375 → $400 | Maintains | Outperform | Get Alert |
| 11/22/2013 | BIIB | Buy Now | Biogen | $114.51 | 153.25% | Evan Seigerman65% | → $290 | Maintains | Outperform | Get Alert |
| 04/04/2013 | BIIB | Buy Now | Biogen | $114.51 | 96.49% | Evan Seigerman65% | $200 → $225 | Maintains | Outperform | Get Alert |
| 03/04/2013 | BIIB | Buy Now | Biogen | $114.51 | 74.66% | Evan Seigerman65% | $185 → $200 | Maintains | Outperform | Get Alert |
| 02/08/2013 | BIIB | Buy Now | Biogen | $114.51 | 61.56% | Evan Seigerman65% | $175 → $185 | Maintains | Outperform | Get Alert |
| 11/12/2012 | REGN | Buy Now | Regeneron Pharmaceuticals | $546.03 | -65.75% | Evan Seigerman65% | → $187 | Initiates | → Outperform | Get Alert |
| 10/08/2012 | BIIB | Buy Now | Biogen | $114.51 | 52.83% | Evan Seigerman65% | $165 → $175 | Maintains | Outperform | Get Alert |
